US-based Dexcom has published positive results for the continuous glucose monitoring (CGM) study (DiaMonD) conducted in diabetes patients on multiple daily injections (MDI) insulin therapy.
DIaMonD is a randomised, controlled study performed at 24 endocrinology practices in the US to evaluate the effect of CGM on A1C and hypoglycemia in participants on MDI insulin regimen.
The data, which was published in the Journal of the American Medical Association (JAMA) on 24 January, indicated that Dexcom CGM system users on MDI have observed a 1% average A1C decrease after 24 weeks of regular use, compared to baseline.
It was also found that CGM users spent more time in target range (70mg to 180mg/dL) and less in hypoglycemia and hyperglycemia, when compared to standard glucose monitoring metre users.
Dexcom president and chief executive officer Kevin Sayer said: "We are delighted that the Dexcom CGM System was able to demonstrate significant benefits among a diverse group of patients, but more importantly, the positive outcomes in the 60+ population will be critical to our efforts in driving CGM coverage for Medicare-eligible patients."
The study was conducted in 158 participants with type one diabetes on MDI and involved usage of Dexcom G4 Platinum CGM System with Software 505.
A subset of subjects with an A1C greater than 8.5% have experienced a 1.3% decrease in A1C from baseline at week 24.
CGM users have also observed a decrease in hypoglycemia during the night with only 0.6% time spent in hypoglycemia compared to 2.9% at baseline, while the time spent in hyperglycemia was also less.
Based on the observed A1C reductions in participants of various education levels, math ability and age, the study also established that CGM is easy to use.